Bio Developments

Pic:getty/vladimirvladimirov

HPV vaccines reduce cervical cancer by 87%: study

By Rachel Arthur

Human papillomavirus (HPV) vaccines reduce cervical cancer rates by 87% in women who were offered the jab between the ages of 12-13, according to a study which analysed data from England's HPV vaccine program.

Pic:getty/blackdovfx

AION Labs spots 'unique opportunity' for AI-driven antibody discovery

By Rachel Arthur

AION Labs, a new innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, has announced a global call for application to identify biomedical scientists and inventors to form a new startup at...

Pic:getty/andrewbrookes

Resilience and Harvard University launch five year R&D alliance

By Rachel Arthur

The new alliance will focus on the development and manufacturing of complex medicines including biologics, vaccines, nucleic acids and cell and gene therapies; as well as looking to launch companies to advance the manufacture of such medicines.

© GettyImages/John M Lund Photography Inc

Marken to add Kenya and Ghana to GMP storage network

By Jane Byrne

Marken, the clinical trial logistics subsidiary of UPS Healthcare, is adding significant capacity to support increased demand for its clinical drug supply chain services, particularly for cell and gene clinical trials.

© GettyImages/courtneyk

Thermo Fisher opens Swiss biologics production facility

By Jane Byrne

The operation of the 1.5 million square-foot biologics manufacturing site in Lengnau, Switzerland is part of a strategic partnership agreed with CSL Limited, announced last year, says Thermo Fisher Scientific.

Pic:getty/sanjeri

Vaccitech to scale up operations with new facility

By Rachel Arthur

Vaccitech has signed a lease for 31,000 sq. ft at Harwell Science and Innovation Campus in the UK, fitting out the facility with a state-of-the art wet laboratory and offices.

Pic:getty/dani3315

Special Edition: Reviewing the advanced therapy pipeline

Atara Biotherapeutics: Developing an off-the-shelf therapy for MS with EBV T-cells

By Rachel Arthur

Atara Biotherapeutics is working on harnessing Epstein-Barr Virus (EBV) T-cells to help develop a new therapy for multiple sclerosis: saying the first-of-its-kind T-cell immunotherapy could not only slow decline but also help patients regain function...